Imperial College London
Alternate

ProfessorPeterSever

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Pharmacology & Therapeutics
 
 
 
//

Contact

 

+44 (0)20 7594 1099p.sever

 
 
//

Assistant

 

Mrs Yvonne Green +44 (0)20 7594 1100

 
//

Location

 

333ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Charytan:2019:10.1016/j.jacc.2019.03.513,
author = {Charytan, DM and Sabatine, MS and Pedersen, TR and Im, K and Park, J-G and Pineda, AL and Wasserman, SM and Deedwania, P and Olsson, AG and Sever, PS and Keech, AC and Giugliano, RP},
doi = {10.1016/j.jacc.2019.03.513},
journal = {Journal of the American College of Cardiology},
pages = {2961--2970},
title = {Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial},
url = {http://dx.doi.org/10.1016/j.jacc.2019.03.513},
volume = {73},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundData on PCSK9 inhibition in chronic kidney disease (CKD) is limited.ObjectivesThe purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function.MethodsThe FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.ResultsThere were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)—preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were −2.5% (95% CI: -4.7% to -0.4%) for stage ≥3 CKD compared with −1.7% (95% CI: -2.8% to 0.5%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.ConclusionsLDL-C lowering and relative clini
AU  - Charytan,DM
AU  - Sabatine,MS
AU  - Pedersen,TR
AU  - Im,K
AU  - Park,J-G
AU  - Pineda,AL
AU  - Wasserman,SM
AU  - Deedwania,P
AU  - Olsson,AG
AU  - Sever,PS
AU  - Keech,AC
AU  - Giugliano,RP
DO  - 10.1016/j.jacc.2019.03.513
EP  - 2970
PY  - 2019///
SN  - 0735-1097
SP  - 2961
TI  - Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial
T2  - Journal of the American College of Cardiology
UR  - http://dx.doi.org/10.1016/j.jacc.2019.03.513
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000470830000007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S0735109719349034?via%3Dihub
UR  - http://hdl.handle.net/10044/1/75008
VL  - 73
ER  -
Download